Latest News and Press Releases

Partnership with KVK, One of the Largest Manufacturers of Controlled Substances in the U.S., Opens the Door for Commercial Launch of APADAZ with PBMs and MCOs KemPharm to Host a Conference Call...

CORALVILLE, Iowa, Oct. 24, 2018 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NASDAQ:KMPH), a specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs, today announced...

Drug Development Approach Combines twoXAR’s Artificial-Intelligence-Driven Drug Discovery Technology with KemPharm’s LATTM Prodrug Technology CORALVILLE, Iowa, Oct. 23, 2018 (GLOBE NEWSWIRE) --...

Event Held Today, October 11, 2018 CORALVILLE, Iowa, Oct. 11, 2018 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NASDAQ:KMPH), a specialty pharmaceutical company focused on the discovery and development of...

CORALVILLE, Iowa, Oct. 05, 2018 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NASDAQ:KMPH), a specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs, today announced...

CORALVILLE, Iowa, Oct. 04, 2018 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NASDAQ:KMPH), a specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs, today announced...

Event to be Webcast Live on Thursday, October 11, 2018, at 8:30 a.m. ET CORALVILLE, Iowa, Oct. 03, 2018 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NASDAQ:KMPH), a specialty pharmaceutical company focused...

NDA Filing for KP415 Anticipated As Soon As First Quarter of 2019 Following Successful Completion of HAP Program Highlights of KP415.A02 Intranasal HAP Trial Results: Mean Drug Liking (Emax) of...

Highlights of KP415.A01 Oral HAP Trial Results: Mean Drug Liking (Emax) of KP415 Prodrug (serdexmethylphenidate) at both 120 mg and 240 mg doses were statistically significantly lower than Focalin®...

CORALVILLE, Iowa, Sept. 05, 2018 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NASDAQ: KMPH), a specialty pharmaceutical company engaged in the discovery and development of proprietary prodrugs, announced...